
II BIENNIAL CONGRESS

of the

European Network for the Study
of Cholangiocarcinoma (ENS-CCA)




Rome / Italy

June 21st 22nd 23rd - 2018

II BIENNIAL CONGRESS

of the

European Network for the Study
of Cholangiocarcinoma (ENS-CCA)



Rome, Italy, June 21st - 22nd - 23rd, 2018

Organized by the

**European Network for the Study of
Cholangiocarcinoma (ENS-CCA)**

<http://www.enscca.org>

or

<http://www.cholangiocarcinoma.eu>

Supported by



SAPIENZA
UNIVERSITÀ DI ROMA



SCIENTIFIC ORGANIZING COMMITTEE

COURSE DIRECTORS

- **Domenico Alvaro, MD** (Sapienza University of Rome, Rome, Italy)
- **Jesús M. Banales, PhD** (Biodonostia Institute, Donostia Hospital, San Sebastian, Spain)
- **Antonio Benedetti, MD** (Marche Polytechnic University, Ancona, Italy)
- **Eugenio Gaudio, MD** (Sapienza University of Rome, Rome, Italy)
- **Marco Marzoni, MD, PhD** (Marche Polytechnic University, Ancona, Italy)

LOCAL ORGANIZING COMMITTEE

- **Maria Consiglia Bragazzi, MD** (Sapienza University of Rome, Rome, Italy)
- **Vincenzo Cardinale, MD** (Sapienza University of Rome, Rome, Italy)
- **Guido Carpino, MD** (Sapienza University of Rome, Rome, Italy)
- **Daniele Costantini, BSC** (Sapienza University of Rome, Rome, Italy)
- **Sabina Di Matteo, BSC** (Sapienza University of Rome, Rome, Italy)
- **Antonio Franchitto, MD** (Sapienza University of Rome, Rome, Italy)
- **Lorenzo Nevi, BSC** (Sapienza University of Rome, Rome, Italy)
- **Paolo Onori, MD** (Sapienza University of Rome, Rome, Italy)
- **Samira Safarikia, BSC** (Sapienza University of Rome, Rome, Italy)



FACULTY

- Gianfranco **D. Alpini** (*Temple, TX, USA*)
- Domenico **Alvaro** (*Rome, Italy*)
- Jesper Bøje **Andersen** (*Copenhagen, Denmark*)
- Mario **Angelico** (*Rome, Italy*)
- Adolfo F. **Attili** (*Rome, Italy*)
- Jesús M. **Banales** (*San Sebastian, Spain*)
- Antonio **Benedetti** (*Ancona, Italy*)
- Pasquale **Berloco** (*Rome, Italy*)
- Chiara **Braconi** (*London, UK*)
- Maria Consiglia **Bragazzi** (*Rome, Italy*)
- Giovanni **Brandi** (*Bologna, Italy*)
- Massimiliano **Cadamuro** (*Milan, Italy*)
- Diego F. **Calvisi** (*Greifswald, Germany*)
- Vincenzo **Cardinale** (*Rome, Italy*)
- Guido **Carpino** (*Rome, Italy*)
- Umberto **Cillo** (*Padua, Italy*)
- Enrico **Cortesi** (*Rome, Italy*)
- Daniele **Costantini** (*Rome, Italy*)
- Sabina **Di Matteo** (*Rome, Italy*)
- Matthias **Evert** (*Regensburg, Germany*)
- Luca **Fabris** (*Padua, Italy*)
- Pier Francesco **Ferrucci** (*Milan, Italy*)
- Trine **Folseraas** (*Oslo, Norway*)
- Laura **Fouassier** (*Paris, France*)
- Antonio **Franchitto** (*Rome, Italy*)
- Heather **Francis** (*Temple, TX, USA*)
- Eugenio **Gaudio** (*Rome, Italy*)



FACULTY

- Felice **Giuliante** (*Rome, Italy*)
- Sergio **Gradilone** (*Austin, MN, USA*)
- Gian Luca **Grazi** (*Rome, Italy*)
- Maria **Guido** (*Padua, Italy*)
- Pietro **Invernizzi** (*Milan, Italy*)
- Shahid A. **Khan** (*London, UK*)
- Marcin **Krawczyk** (*Homburg, Germany - Warsaw, Poland*)
- Guro Elisabeth **Lind** (*Oslo, Norway*)
- José Juan García **Marin** (*Salamanca, Spain*)
- Marco **Marzioni** (*Ancona, Italy*)
- Joachim C. **Mertens** (*Zurich, Switzerland*)
- Kari **Nejak-Bowen** (*Pittsburgh, PA, USA*)
- Lorenzo **Nevi** (*Rome, Italy*)
- Paolo **Onori** (*Rome, Italy*)
- Hector **Perez Montoyo** (*Barcelona, Spain*)
- Marco **Rengo** (*Rome, Italy*)
- Lewis **Roberts** (*Rochester, MN, USA*)
- Massimo **Rossi** (*Rome, Italy*)
- Hanna **Sanger** (*Homburg, Germany*)
- Samira **Safarikia** (*Rome, Italy*)
- Satdarshan P. **Singh Monga** (*Pittsburgh, PA, USA*)
- Mario **Strazzabosco** (*New Haven, CT, USA*)
- Silverio **Tomao** (*Rome, Italy*)
- Sabine **Urban** (*Homburg, Germany*)
- Silvestre **Vicent** (*Pamplona, Spain*)
- Marco **Vivarelli** (*Ancona, Italy*)
- Huiping **Zhou** (*Richmond, VA, USA*)



SCIENTIFIC INFORMATION

Cholangiocarcinoma (CCA) is a heterogeneous group of malignancies that may originate from every portion of the biliary tree. It is the second most common primary liver tumor and the incidence is increasing worldwide. CCA has a very bad prognosis due to its aggressiveness, late diagnosis and treatment refractory nature.

In May 2015, the European Network for the Study of Cholangiocarcinoma (ENS-CCA: www.enscca.org / www.cholangiocarcinoma.eu) was created to promote and boost international research collaborations on the study of CCA at basic, translational and clinical level [Banales JM, et al. *Nature Reviewers Gastroenterology & Hepatology* 2016].

The network is established by 33 active research groups from **12 European countries**, including an International Advisory Board of distinguished collaborators from USA, **most EASL Members**. A European Registry Data Collection on Cholangiocarcinoma (CCA) was created as one of the first initiative (also supported by EASL). Currently, data from more than 1500 patients have been collected and we expect to significantly increase this number in the next two years.

A main goal of the registry is to create a virtual biobank of biologic samples (biopsies, serum, etc.) from CCA patients. Apart from the registry a number of collaborative multicenter studies have been planned within the network on different areas of CCA including: **Basic Science, Histo-morphology characterization, Molecular profiling, Epidemiology and clinical characterization (including clinical trials) and Early diagnosis biomarkers and tools.**



The II Biennial Congress of the network has been organized with the following main objectives:

- To update all the participants on the progress of the “Registry”.
- To discuss potential improvement of the “Registry” organization and future developments;
- To discuss Registry data so far collected on CCA patients, including classification, morphology, risk factors etc.
- To discuss preliminary results and the progress of collaborative studies so far organized;
- To propose new multicenter collaborative studies with particular attention to:
 - “surveillance of population at risk”
 - “genetic and epigenetics”
 - “biomarkers for diagnosis and prognosis”
 - “new diagnostic tools”
 - “targeted therapies”
- To discuss feedback of the application to the European cost-grant To plan future applications for European funds including “Horizon2020”

FINAL PROGRAMME

Thursday, June 21st 2018

17.00-18.00 Registration

18.00-18.15 Welcome from local authorities

Introductory remarks

Domenico Alvaro (*Rome, Italy*)

Jesús M. Banales (*San Sebastian, Spain*)

Antonio Benedetti (*Ancona, Italy*)

Eugenio Gaudio (*Rome, Italy*)

Marco Marzioni (*Ancona, Italy*)

18.15-18.30 The European Registry Data Collection on Cholangiocarcinoma: an update

Jesús M. Banales (*San Sebastian, Spain*)

18.30-18.45 The European Histology Registry on Cholangiocarcinoma: an update!

Guido Carpino (*Rome, Italy*)

18.45-19.15 General Discussion

Friday, June 22nd 2018

- 08.30-09.50 Genetic and Epigenetic**
Chairs: Jesper Bøje Andersen
(Copenhagen, Denmark)
Marcin Krawczyk
(Homburg, Germany - Warsaw, Poland)
- 08.30-08.50 Validation phase of GWAS on CCA: new collaborative project**
Lewis Roberts (Rochester, MN, USA)
- 08.50-09.10 Genomic and epigenomic stratification of cholangiocarcinoma**
Jesper Bøje Andersen (Copenhagen, Denmark)
- 09.10-09.30 Genetics of cholangiocarcinoma in pre-defined subgroups of patients - proposal of a NGS-based study**
Marcin Krawczyk (Homburg, Germany - Warsaw, Poland)
- 09.30-09.50 Whole exome sequencing of primary sclerosing cholangitis- associated biliary tract cancer**
Trine Folseraas (Oslo, Norway)

Friday, June 22nd 2018

- 09.50-11.30 Pathology and Signaling**
Chairs: Mario Angelico (*Rome, Italy*)
Giovanni Brandi (*Bologna, Italy*)
Diego F. Calvisi (*Greifswald, Germany*)
- 09.50-10.10 **Role of the melatonin/Menin axis in the regulation of cholangiocarcinoma growth**
Gianfranco D. Alpini (*Temple, TX, USA*)
- 10.10-10.30 **Bile acids and sphingolipids in cholangiocarcinoma.**
Huiping Zhou (*Richmond, VA, USA*)
- 10.30-10.50 **Cellular and molecular mechanisms of cholangiocarcinoma**
Kari Nejak-Bowen, Satdarshan P. Singh Monga, (*Pittsburgh, PA, USA*)
- 10.50-11.10 **Identification of key oncogene effectors in mutant KRAS Cholangiocarcinoma through integrative gene-expression analyses and mouse genetics: the role of the transcription factor FOSL1/AP-1**
Silvestre Vicent (*Pamplona, Spain*)
- 11.10-11.30 **News from ENS-CCA Members**
Why ICD Coding for Cholangiocarcinoma needs to be changed
Shahid A. Khan (*London, UK*)
- 11.30-11.50 *Coffee Break*

Friday, June 22nd 2018

- 11.50-13.10 Tumor/stroma interaction**
Chairs: Enrico Cortesi (*Rome, Italy*)
Laura Fouassier (*Paris, France*)
Mario Strazzabosco (*New Haven, CT, USA*)
- 11.50-12.10 The immunoregulatory role of tumor associated dendritic cells (taDCs) in the development and progression of cholangiocarcinoma**
Hanna Sanger (*Homburg, Germany*)
- 12.10-12.30 Targeting tumor-stroma interactions to prevent lymph node metastatisation in CCA**
Luca Fabris (*Padua, Italy*),
Massimiliano Cadamuro (*Milan, Italy*),
Mario Strazzabosco (*New Haven, CT, USA*)
- 12.30-12.50 Cholangiocarcinoma Patient Derived Organoids as a novel tool for personalized medicine and functional tumour characterization**
Chiara Braconi (*London, UK*)
- 12.50-13.10 Development, histopathological characterization, and signaling pathways investigation of novel mouse models of intrahepatic cholangiocarcinoma based on recently identified mutations**
Diego F. Calvisi (*Greifswald, Germany*)
Matthias Evert (*Regensburg, Germany*)
- 13.10-14.30 *Light Lunch***

Friday, June 22nd 2018

- 14.30-15.50** **Biomarkers and diagnostic tools (1st part)**
Chairs: Adolfo F. Attili (*Rome, Italy*)
 José Juan García Marin (*Salamanca, Spain*)
 Joachim C. Mertens (*Zurich, Switzerland*)
- 14.30-14.50** **Usefulness of plasma membrane transporters as biomarkers and molecular targets in cholangiocarcinoma**
 José Juan García Marin (*Salamanca, Spain*)
- 14.50-15.10** **The big myth, liquid biopsy for the identification and differentiation between HCC and CCA, can it be done?**
 Sabine Urban (*Homburg, Germany*)
- 15.10-15.30** **Detecting cholangiocarcinomas in PSC patients using liquid biopsy analyses**
 Guro Elisabeth Lind (*Oslo, Norway*)
- 15.30-15.50** **International validation of a panel of prognostic biomarkers for CCA in tumor tissue of patients undergoing surgical resection**
 Jesús M. Banales (*San Sebastian, Spain*)

Friday, June 22nd 2018

- 15.50-16.50** **Biomarkers and diagnostic tools (2nd part)**
Chairs: Trine Folseraas (*Oslo, Norway*)
Pietro Invernizzi (*Milan, Italy*)
Silverio Tomao (*Rome, Italy*)
- 15.50-16.10 **International validation of novel protein biomarkers present in serum extracellular vesicles for the diagnosis of PSC, CCA, HCC**
Jesús M. Banales (*San Sebastian, Spain*)
- 16.10-16.30 **Asbestos and intrahepatic cholangiocarcinoma: searching for molecular biomarkers of exposure by next generation sequencing**
Giovanni Brandi (*Bologna, Italy*)
- 16.30-16.50 **International cholangiocarcinoma imaging registry database and correlation studies with histo-morphology and genomics (radiogenomic)**
Vincenzo Cardinale, Guido Carpino, Marco Rengo (*Rome, Italy*)
- 16.50-17.00 *Coffee Break*
- 17.00-18.00** **Oral communications (from young investigators)**
Chairs: Gianfranco D. Alpini (*Temple, TX, USA*)
Massimo Rossi (*Rome, Italy*)
Satdarshan P. Singh Monga (*Pittsburgh, PA, USA*)
- 17.00-17.15 **Liver metastases from intrahepatic cholangiocarcinoma: does current staging classification reflect patient outcomes?**
A. Lamarca, R. Pihlak, M. McNamara, R. Hubner, J.W. Valle
Manchester (UK)

- 17.15-17.30 **Combined therapy with CDK4/6 and mTOR inhibitors is highly effective in a novel murine AKT/YAP-induced model of experimental intrahepatic cholangiocarcinoma**
K. Utpatel, X. Song, K. Evert, S. Zhang, B. Fan, L. Che, M.G. Pilo, A. Cigliano, X. Liu, S. Ribback, F. Dombrowski, X. Chen, M. Evert, D.F. Calvisi
Regensburg (Germany), San Francisco (CA, USA), Greifswald (Germany), Shanghai (China)
- 17.30-17.45 **Usefulness of serum metabolomic profiles as diagnostic biomarkers for cholangiocarcinoma, hepatocellular carcinoma and primary sclerosing cholangitis**
E. Lozano, J.M. Banales, M. Iñarrairaegui, A. Arbelaz, P. Milkiewicz, J. Muntane, L. Muñoz-Bellvis, A. La Casta, L.M. Gonzalez, E. Arretxe, C. Alonso, I. Martínez-Arranz, L. Bujanda, J.J.G. Marin, B. Sangro, R.I.R. Macias
Salamanca (Spain), Madrid (Spain), San Sebastian (Spain), Bilbao (Spain) Pamplona (Spain), Warsaw (Poland), Seville (Spain) Derio (Spain)
- 17.45-18.00 **Role of protease-inhibitor SerpinB3 in human cholangiocarcinoma stem-like compartment**
M. Correnti, C. Raggi, A. Cappon, J.B. Andersen, E. Forti, G. Cavalloni, E. Torchio, F. Marra, P. Pontisso
Padua (Italy), Florence (Italy), Copenhagen (Denmark), Candiolo (TO, Italy)

18.00-19.00

**General Meeting of the Members of the
ENS-CCA (1st part)**

• **Cost Grant action: update**

Vincenzo Cardinale (*Rome, Italy*)

• **Guidelines of ENS-CCA**

Marco Marzioni (*Ancona, Italy*)

• **Proposals of grant applications**

Chairs: Domenico Alvaro (*Rome, Italy*)

Jesper Bøje Andersen (*Copenhagen, Denmark*)

Jesús M. Banales (*San Sebastian, Spain*)

Saturday, June 23rd 2018

- 09.00-10.00** **Oral communications (from young investigators)**
Chairs: Antonio Benedetti (*Ancona, Italy*)
Chiara Braconi (*London, UK*)
Gian Luca Grazi (*Rome, Italy*)
- 09.00-09.15 **Highthroughput screening technologies identified MIR249 as a modulator of chemo-resistance in cholangiocarcinoma**
P. Carotenuto, V. Cardinale, M. Fassan, C. Vicentini, A. Scarpa, A. Lampis, L. Cascione, D. Costantini, D. Alvaro, M. Ghidini, F. Trevisani, N. Valeri, R. Te Poele, M. Pannella, S. Ventura, M. Salati, L. Boulter, R. Guest, S. Forbes, M. Rugge, U. Cillo, R. Begum, E. Smyth, D. Cunningham, L. Rimassa, A. Santoro, M. Roncalli, P. Clarke, P. Workman, R. Chopra, C. Braconi
London (UK), Rome (Italy), Padua (Italy), Verona (Italy), Bellinzona (Switzerland), Edinburgh (UK) Milan (Italy)
- 09.15-09.30 **HSP90 inhibition drives degradation of cholangiocarcinoma FGFR2 fusion proteins, improving tumor targeting by FGFR kinase inhibitors**
D. Lamberti, G. Cristinziano, M. Porru, C. Leonetti, C.A. Amoreo, S. Buglioni, M.J. Borad, S. Anastasi, O. Segatto
Rome (Italy), Scottsdale (USA)
- 09.30-09.45 **Role of A.L.P.P.S. in treatment of perihilar cholangiocarcinoma: experience of single centre**
F. Mocchegiani, R. Montalti, M. Vivarelli
Ancona (Italy)

Saturday, June 23rd 2018

09.45-10.00 **Necroptosis is associated with a better survival in intrahepatic cholangiocarcinoma**
D. Sacchi, U. Cillo, S. Sarcognato, E. Gringeri, L. Fabris, M. Di Giunta, L. Nicolè, V. Guzzardo, M. Guido
Padua (Italy)

10.00-11.00 **General Meeting of the Members of the ENS-CCA (2nd part)**

- **ENS-CCA and EASL, ongoing initiatives: update**
Marco Marzioni (*Ancona, Italy*)

- **Initiatives for the future**

Jesús M. Banales (*San Sebastian, Spain*)

Chairs: Domenico Alvaro (*Rome, Italy*)

Jesús M. Banales (*San Sebastian, Spain*)

Jesper Bøje Andersen (*Copenhagen, Denmark*)

11.00-12.40 **NOVEL THERAPIES**

Chairs: Pasquale Berloco (*Rome, Italy*)

Felice Giuliante (*Rome, Italy*)

Marco Vivarelli (*Ancona, Italy*)

11.00- 11.20 **ABTL0812, a novel TRIB3 mediated autophagy inducer towards clinical development for cholangiocarcinoma**

Hector Perez Montoyo (*Barcelona, Spain*)

11.20-11.40 **Percutaneous Hepatic Perfusion vs. Cisplatin/ Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma**

(Delcath PHP-ICC-203 clinical study)

Pier Francesco Ferrucci (*Milan, Italy*)

Saturday, June 23rd 2018

- 11.40-12.00 **Targeting SUMOylation dependent S100A4 Nuclear Import by Low-Dose Paclitaxel in Patients with Cholangiocarcinoma (CCA) undergoing Surgical Resection and Liver Transplantation**
Umberto Cillo, Luca Fabris, Maria Guido
(Padua, Italy)
- 12.00-12.20 **Blocking cholangiocarcinoma tumor growth, angiogenesis and EMT using antihistamine treatments & inhibiting mast cell migration**
Heather Francis *(Temple, TX, USA)*
- 12.20-12.40 **Primary cilia expression in CCA: from prognostic marker to preventive and therapeutic target**
Sergio Gradilone *(Austin, MN, USA)*
- 12.40-13.00 **CONCLUSIVE REMARKS**
Domenico Alvaro *(Rome, Italy)*
Jesús M. Banales *(San Sebastian, Spain)*



GENERAL INFORMATION

Congress Venue

Sapienza University of Rome
Department of Anatomy
Viale Regina Elena, 289
00161 Rome, Italy

Organizing Secretariat

Spazio Congressi S.r.l.
Via Alfredo Catalani, 39
00199 Rome, Italy
Tel.-Fax: 0039 06 86204308
Email: spazio.c@mclink.it

Registration

Conference Registration is free and reserved up to 150 attendees.
Registration includes:

- Access to scientific sessions
- Lunch, Coffee Breaks
- Attendance Certificate

To register please contact the Organizing Secretariat Spazio Congressi

Language

The official language of the conference is English. Simultaneous translation will not be provided.

Discover the city of Rome, Italy

City Web Site: <http://www.turismoroma.it/?lang=en>

Public Transportation: <http://www.atac.roma.it/index.asp?lingua=ENG>

Climate

<https://weather.com/weather/5day//ITXX0067:1:IT>

Thanks to an unrestricted grant from:

